Intercell's acquisition of Iomai approved
This article was originally published in Scrip
Executive Summary
Intercell's acquisition of Iomai was approved by the US-based vaccine specialist's shareholders in a meeting held on August 1st. Intercell will now acquire Iomai for $6.60 per share of the company's common stock, representing a total payment of $189 million. The acquisition, which is expected to close within the next few days, was approved by 99.97% of the votes cast, representing over 71% of the outstanding shares entitled to vote at the meeting.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.